DENN domain containing 2AGenealiases: FAM31D · KIAA1277
Q-omics provides the consensus-scored DENND2A profile across patient tissues and cancer cell-line models. DENND2A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, DENND2A is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, DENND2A RNA expression shows 18,042 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, BLCA, and TGCT as cancer lineages where DENND2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND2A survival associations across molecular data types. DENND2A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND2A RNA expression–survival associations across cancer types. High DENND2A expression shows unfavorable associations in LUSC, MESO, BLCA and LGG, but favorable associations in COAD and READ. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for DENND2A RNA expression.
This table summarizes DENND2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DENND2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND2A shows lower tumor expression in BLCA, COAD, THCA, KICH, LUAD and LUSC. The BLCA box plot shows higher DENND2A RNA expression in normal versus tumor tissue (log2 FC = −3.014, t-test p < 0.001).
This table shows molecular features associated with DENND2A in patient tissues and cancer cell lines. In patient samples, DENND2A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
